New assays have been released today! CPTAC and researchers from the University of Victoria – Genome British Columbia Proteomics Centre just released over 130 quantitative, fit-for-purpose, multiplexed mouse multiple reaction monitoring (MRM) mass spectrometry (MS)-based plasma assays for public use...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
All | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
Displaying 101 - 120 of 241July 30, 2019
CPTAC researchers at John Hopkins University School of Medicine have developed a technique to reliably identify o-linked glycosylation sites and site-specific glycans with core 1 st...
July 23, 2019
Proteomic profiling often entails using a large sample input to explore the dynamic nature of protein expression and regulation. However, there are instances when researchers have the opposite due to prior methodology such as fluorescence activated cell sorting (FACS) or when dealing with patient...
July 17, 2019
June 13th, 2019 marked the addition of our 33rd institution to the International Cancer Proteogenomic Consortium (ICPC). We are pleased to include Amsterdam UMC as a...
July 5, 2019
The National Cancer Center - Korea (NCC-K) joins the International Cancer Proteogenome Consortium (ICPC) global partnership. The NCC-K has joined the ranks of...
July 2, 2019
While it’s a common misconception that all tumors in the brain are the same, there are more than 120 subtypes of brain cancers with very diverse features and diagnosis.
June 27, 2019
Dr. Henry Rodriguez gave the keynote address at the 62nd Annual Meeting of the Japanese Society of Nephrology in Nagoya, Japan this week. In line with the conference’s theme Open The Future, Dr.
June 13, 2019
Since its first mention in the scientific literature in 2004 by Jaffe et al1, the term proteogenomics has been shrouded in mystery and thick technical language. It is a complex idea, but one that is gaining traction as its value to improve our understanding of cancer development and potentially...
June 4, 2019
Phosphorylation is a key process in the regulation of protein activity and has long been appreciated as an essential mechanism for the control of cellular function - tells a protein where to go, what to bind to and even when to die.
May 28, 2019
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to release its newest comprehensive dataset - deep proteomic/phosphoproteomic data and imaging data of Lung Adenocarcinoma (LUAD) patient tumors. The CPTAC Tumor Characterization Program uses proteogenomic analysis to systematically...
May 14, 2019
Riding the wave of the future requires scientists to move away from silo-thinking to an inclusive and collaborative mind set. By leveraging the power of crowdsourcing, precisionFDA and NCI-CPTAC teamed up to launch the Multi-omics Enabled Sample Mislabeling Correction Big Data Challenge. Over 500...
April 25, 2019
Analyzing both the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor that points at novel cancer biological mechanisms and possible new therapeutic strategies.
April 8, 2019
Is DNA sequencing enough to recommend personalized treatments for cancer patients? In a article published in Nature Reviews Clinical Oncology, CPTAC investigators and colleagues from the Fred Hutch, Baylor College of Medicine, and University of Washington Medicine make the case for proteogenomics -...
April 2, 2019
CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer.
March 14, 2019
"Big data" is a term to describe data sets so large or complex that traditional data processing strategies are inadequate. As continued advancements in biomedical technologies generate an increasing amount of patient data, administration of patient-centered care will depend, in part, on the ability...
March 7, 2019
In February 2019, the precisionFDA and the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) (in coordination with DREAM Challenges) proudly announced the best performers in the first-ever...
March 4, 2019
It is no coincidence that one cellular process is mentioned time and time again in discussions of cell-signaling pathways in cancer - that is phosphorylation. Since its discovery, it has come to be recognized as a global regulator of many intracellular processes such as growth, proliferation, and...
February 25, 2019
In biomedical research, sample mislabeling, or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample...
February 19, 2019
University of Michigan Rogel Cancer Center researchers Arul Chinnaiyan, Alexey Nesvizhskii and colleagues have recently teamed up to catalog circular RNA (circRNA) in multiple cancers and conducted initial research that suggests these stable structures could serve as cancer markers in blood or urine...
February 15, 2019
Integrative proteogenomic methods use mass spectrometry (MS)-based proteomic database for identifying new genomic alterations and validating novel protein sequences as potential disease biomarkers or therapeutic targets. The customized database approach is time consuming and not feasible for real-...